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Abstract
Background: A large variety of proteins involved in inflammation, coagulation, lipid-oxidation and lipid
metabolism have been associated with high-density lipoprotein (HDL) and it is anticipated that changes in the
HDL proteome have implications for the multiple functions of HDL. Here, SELDI-TOF mass spectrometry (MS) was
used to study the dynamic changes of HDL protein composition in a human experimental low-dose endotoxemia
model. Ten healthy men with low HDL cholesterol (0.7+/-0.1 mmol/L) and 10 men with high HDL cholesterol
levels (1.9+/-0.4 mmol/L) were challenged with endotoxin (LPS) intravenously (1 ng/kg bodyweight). We previously
showed that subjects with low HDL cholesterol are more susceptible to an inflammatory challenge. The current
study tested the hypothesis that this discrepancy may be related to differences in the HDL proteome.
Results: Plasma drawn at 7 time-points over a 24 hour time period after LPS challenge was used for direct capture of
HDL using antibodies against apolipoprotein A-I followed by subsequent SELDI-TOF MS profiling. Upon LPS
administration, profound changes in 21 markers (adjusted p-value < 0.05) were observed in the proteome in both study
groups. These changes were observed 1 hour after LPS infusion and sustained up to 24 hours, but unexpectedly were
not different between the 2 study groups. Hierarchical clustering of the protein spectra at all time points of all
individuals revealed 3 distinct clusters, which were largely independent of baseline HDL cholesterol levels but correlated
with paraoxonase 1 activity. The acute phase protein serum amyloid A-1/2 (SAA-1/2) was clearly upregulated after LPS
infusion in both groups and comprised both native and N-terminal truncated variants that were identified by two-
dimensional gel electrophoresis and mass spectrometry. Individuals of one of the clusters were distinguished by a
lower SAA-1/2 response after LPS challenge and a delayed time-response of the truncated variants.
Conclusions: This study shows that the semi-quantitative differences in the HDL proteome as assessed by SELDI-
TOF MS cannot explain why subjects with low HDL cholesterol are more susceptible to a challenge with LPS than
those with high HDL cholesterol. Instead the results indicate that hierarchical clustering could be useful to predict
HDL functionality in acute phase responses towards LPS.
Introduction
High-density Lipoprotein (HDL) cholesterol levels are
inversely associated with a risk for cardiovascular disease
[1]. LDL cholesterol lowering drugs have been proven to
be successful, however up to 65% of cardiovascular death
cannot be prevented which explains the strong interest in
HDL increasing strategies [2].
Intensive research over the past decade has elucidated
the involvement of HDL in multiple pathways in
atherogenesis. Besides hyper- and hypolipidemia, oxida-
tion of lipoproteins and coagulation and fibrinolysis [3],
Iinflammation is suggested to be one of the fields in
which HDL and HDL-associated proteins [4] affect the
course of acute infection. As a result, the consequential
systemic inflammatory response may have a causal
impact on atherosclerosis [5].
Proteomic biomarker search has been recently applied to
HDL to achieve more insight into the functions and pro-
tein composition of this lipoprotein class [6-8]. Assess-
ment of 1-dimensional electrophoresis (DE) and 2-DE-
matrix-assisted laser desorption ionisation-time of flight,
Isotope-coded Affinity Tag and Western-blot analysis has
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led to the identification of 56 HDL-associated proteins
[9,10]. Importantly, Vaisar et. al. identified 42 HDL-asso-
ciated proteins that differed substantially in amount
between HDL from CAD patients and controls [11]. Serial
sample analysis with the above mentioned approaches are
labor intensive which prompted us establish a high-
throughput HDL profiling technique [9]. Moreover, serial
profiling of the HDL proteome might be a welcome addi-
tion to reveal information about the dynamic processes
that occur compared to single “snapshot” approaches. The
current study focuses on the HDL protein dynamics by
means of SELDI-TOF MS after an endotoxin intervention
in healthy volunteers.
Methods
Study Participants
Healthy male subjects with plasma HDL cholesterol
levels < 10th percentile (low HDL group, n = 10) and
healthy age-matched male subjects with plasma HDL
cholesterol levels > 90th percentile (high HDL group, n =
10), were recruited for endotoxin challenge [12]. In addi-
tion, normolipemic males (n = 4; HDL cholesterol levels
1.4 +/- 0.3 mM) were recruited as controls for a vehicle
bolus. Written informed consent was obtained from all
participants and the study protocol was approved by the
institutional review board of the Academic Medical
Center.
Study Design
The study was performed as described [12]. In brief, study
participants were required to refrain from alcohol and caf-
feine-containing beverages at least 24 hours before the
study. On the morning of the study day at 7:30 AM after
an overnight fast, study participants were admitted to the
research unit. At 7.45 AM a catheter was inserted in an
antecubital vein of each arm. At 8.00 AM (time [t] 0),
blood was drawn for baseline measurements. Subse-
quently, subjects received a bolus infusion of 1 ng/kg body
weight of endotoxin (Escherichia coli lipopolysaccharide,
catalog number 1235503, lot G2B274; United States Phar-
macopeial Convention Inc, Rockville, MD) in the antecu-
bital vein of the contralateral arm. Healthy controls
received a vehicle bolus to control for any diurnal effects.
Blood samples were collected at t = 0, 1, 2.5, 4, 6, and
8 hours after endotoxin challenge. The next morning at
8.00 AM, 24 hours after endotoxin infusion, study partici-
pants returned after an overnight fast for a final blood
withdrawal.
Blood collection
Blood was collected in EDTA or heparin, kept on ice,
and centrifuged at 2000g for 20 minutes at 4°C. Plasma
was snap-frozen and stored at -80°C until analysis.
Inflammatory marker protein measurements
Serum amyloid A (SAA) ELISA was carried out using a kit
from Anogen biotech Laboratories (Mississauga, Ontario,
Canada). PON-1 activity measurements were performed in
heparinized plasma as described previously [13].
Sample preparation and HDL capture
SELDI-TOF MS analysis was performed as described [9].
Complete time series of plasma of each participant was
used for analyses on separate spots on PS20 chips (in
triplicate). In short, native HDL was directly captured
from 100 μL diluted EDTA plasma (1:2 diluted with
Tris Buffered Saline pH 7.4) which was incubated on
chips coated with antibodies against apo A-I for 2 hours
at room temperature on a horizontal shaker (600 rpm).
The chips were subsequently washed 4 times with TBS
for 10 minutes, followed by a 5 minute TBS-Tween
(0.005%) rinse and a final wash step with Hepes solution
(5 mM). All spots were allowed to dry and subsequently
1.2 μL sinapinic acid (10 mg/ml in 50/49.9/0.1% acetoni-
tril/H2O/TFA) was applied to each spot.
SELDI-TOF analysis and data preprocessing
Spectra were recorded at two laser intensities of 203 to
210 relative units and the focus mass was set to 28 kDa.
Spectra were generated with approximately 100 shots at
13 positions per SELDI spot. Analysis was carried out
using a PBS IIc protein chip reader (Ciphergen Biosys-
tems, Fremont, CA, USA) using an automated data collec-
tion protocol of the Protein-Chip Software (version 3.1.1.).
Data were collected up to 150,000 kDa. Calibration was
performed using a protein calibration chip (Bio-Rad). All
spectra were automatically corrected for baseline values
and spot to spot correction was assessed by the Ciphergen
protein chip software. Finally, since the HDL-capture
design was based on a 100% chip saturation with HDL
particles, all spectra were normalized on apo A-I signal.
HDL isolation for two-dimensional gel electrophoresis
(2-DE), protein quantification and identification
HDL isolation of six subjects, three representing the high
HDL and three the low HDL groups, was performed
before (t = 0) and after (t = 8) LPS challenge as described
previously [6]. In brief, 5 mL of EDTA-plasma, adjusted
to a density of 1.24 g/mL with solid KBr (0.3816 g/mL)
was layered in the bottom of a centrifuge tube. The
plasma fraction was then overlaid with KBr/phosphate
solution (0.083 4 g/mL, density 1.063 g/mL). Ultracentri-
fugation was performed in a Beckman XL-90 equipped
with a Ti 70 rotor at 290 000*g for 4 hours at 15°C. The
fractions corresponding to HDL2 and HDL3 were col-
lected with a syringe and a second ultracentrifugation
step (KBr/phosphate solution, density of 1.24 g/mL) was
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performed for 2 hours to eliminate the presence of
plasma contaminants. HDL proteins were desalted using
PD-10 columns and protein concentration was measured
using Bio-Rad protein assay. 2-DE was performed using
IPGphor and Multiphor, Amersham Biosciences. HDL
proteins (300 μg) were applied by in gel rehydration for
12 hours at low voltage (30 V) in pH 3-10NL IPGs strips.
Proteins were then focused at 53000 Vh at max voltage
of 8000 V. The second dimension was performed by
transferring the proteins to a homogenous gel (T = 14%,
C = 1.5%) running at 40-800 V, 10°C, 20-40 mA over-
night. Separated proteins were stained by Sypro Ruby
(Molecular Probes, USA). Images of the protein patterns
were analyzed by a CCD camera in a UV-scanning illu-
mination mode (Flour-S Multi-Imager, Bio-Rad, USA)
combined with a computerized imaging 12-bit system
(PDQuest 2-D gel analysis software, Bio-Rad).
Proteins were quantified as fluorescence intensity
(counts) per total fluorescence on the 2-D gels,
expressed in %. Proteins were identified by peptide mass
fingerprinting of tryptic peptides using Matrix Assisted
Laser Desorption/Ionization Time of Flight MS (MALDI
TOF MS) (Voyager DE Pro, Applied Biosystems, USA)
prior to database searches as described previously.
Bioinformatics and statistics
Prior to statistical analysis all generated spectra were pre-
processed as described before [14]. In brief, each individual
m/z spectrum was divided into non-overlapping intervals
whose sizes are increasing proportionally with the mass
over charge (m/z) values. The size of an interval starting at
3000 (m/z) is computed as m.r with r fixed at 0.5% in all
our results below. The intensity associated with each inter-
val was taken as the sum of the intensities over the inter-
val. Discretisation of the m/z axis leads to a reduction of
the number of variables down to 704 m/z intervals.
Subsequently, a statistical test was performed for
removal of the m/z intervals over which the intensity
did not significantly change over time. For that purpose,
the non-parametric Kruskal-Wallis one-way analysis of
variance method was used for testing the equality of
population medians among the 7 time points; 104 m/z
intervals at the low laser intensity and 77 m/z intervals
at the high laser intensity showed a p-value lower than
0.05. Raw p-values were then adjusted for multiple test-
ing using Benjamini and Hochberg’s method. This
reduced the number of significant intervals down to 21
and 14, respectively. Since the high laser intensity
showed less sensitivity, we restricted our analysis to the
low laser intensity.
Hierarchical clustering was performed using, for each
individual, the mean (of the triplicates) dynamics of all
21 significant markers. Hierarchical clustering was com-
puted using an agglomerative approach with complete
linkage and one minus the correlation (1-r) as a distance
measure. All analyses were performed with Matlab®
(The MathWorks Inc., Natick, MA, USA).
Results
We previously showed that infusion of endotoxin at
1 ng/kg bodyweight in healthy human volunteers with
low and high HDL cholesterol levels did not affect
changes in the absolute plasma levels of HDL choles-
terol and apo A-I (Additional file 1, Figure S1) [12]. In
the same study, it was shown that individuals with lower
HDL cholesterol levels were more susceptible to this
inflammatory stimulus based on leukocyte response,
cytokine response and clinical symptoms compared to
those with higher HDL cholesterol levels. The current
study in which a subset (Table 1) of the original study
cohort was used focuses on the changes in the HDL
proteome.
Serial HDL proteome profiling
For each time point, plasma HDL was directly captured
using anti apo A-I antibodies on PS-20 protein-chips
after which protein spectra were generated by SELDI-
TOF mass spectrometry [9]. Figure 1A gives a represen-
tative overview of the HDL proteome changes over time
following LPS administration of which serum amyloid-1
(SAA-1) could be confirmed with ELISA (Figure 1B). To
study the dynamic changes in more detail, each spec-
trum was divided in 704 m/z marker intervals.
In a next step, we generated heatmaps of the marker
regions with the most prominent changes (Left panels
of Figure 2). In each heatmap, the relative intensities
from all timepoints of the indicated m/z region in the
HDL spectrum are presented. The most significant
changes were found in the low mass region (up to 20
kDa, Additional file 2, Table S1). Different types of
Table 1 Characteristics of the study subjects
Unit Low HDL (n = 10) High HDL (n = 10)
Age (Years) 30 ± 17 34 ± 14
BMI (kg/m2) 23.1 ± 5.7 22.4 ± 4.7
HDL-chol (mM) 0.78 ± 0.14 * 1.98 ± 0.41 *
LDL-chol (mM) 2.50 ± 0.55 2.62 ± 0.84
Apo A-I (g/L) 1.0 ± 0.2 * 1.7 ± 0.2 *
Apo B (g/L) 1.1 ± 0.2 1.0 ± 0.2
hsCRP (g/L) 3.8 ± 4.8 1.5 ± 1.5
Total Chol (mM) 3.84 ± 0.71 5.20 ± 1.10
IMT (mm) 0.59 ± 0.11 0.54 ± 0.05
BMI, body mass index; HDL-chol, high-density lipoprotein cholesterol; LDL-chol,
low-density lipoprotein cholesterol; Apo A-I indicates apolipoprotein A-I; apo B,
apolipoprotein B; hsCRP, high-sensitivity C-reactive protein; IMT, intima-media
thickness. All data are expressed as mean ± SD. * indicates P-value < 0.001
(Independent Student t-test).
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Figure 1 Changes in HDL composition upon LPS challenge.A. Virtual gel-views representing the HDL composition after SELDI-TOF MS
analysis. Depicted are profiles from on-chip captured HDL from baseline (BL) to 24 hours after endotoxin challenge. All spectra were normalized
on total ion current and baseline corrected and subsequently translated to the “virtual gel-view” output format. The arrows indicate those
markers which demonstrated a significant dynamic change over time (adjusted p < 0.05) after LPS challenge. B. SAA response in healthy
individuals after LPS challenge. SAA levels, of the low (white bars) and high (black bars) HDL cholesterol groups, as determined by ELISA, are
depicted. The data represent mean ± SD. * indicates statistical significant difference between the low and high cholesterol HDL group (p < 0.05).
From t = 4 hours and all following timepoints a statistical significant difference compared to baseline condition was reached (p < 0.001).
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dynamics, as shown in the plots of the dynamics in fig-
ure 3, were observed such as a gradual decrease in the
3000-3138 m/z marker interval, and a rise and fall with
a maximum at t = 2.5 hours after endotoxin infusion in
the 3450-3537 m/z marker interval. In the higher mass
regions, a gradual decrease in marker intensity could be
observed in the 34040-34553 m/z marker interval
whereas in the 45915-47310 m/z marker interval a rise
and fall with a maximum at t = 4 hours was seen
(Figure 3).
In further analyses, we pooled the data of both study
groups and found that 104 of the 704 m/z intervals
changed significantly (p < 0.05) over the time course of
the experiment, among which 21 remained significant
after multiple testing correction (Additional file 2, Table
S1). In the 4 control subjects, infused with vehicle, none
of these 104 marker intervals changed significantly over
the 24 hour time period indicating that diurnal rhythm
was unlikely to cause the observed changes (Additional
file 2, Table S1, right column).
A B
C2
C2
C2
C2
Figure 2 Heat map overviews of the mass/charge (m/z) regions of the relevant changes in HDL dynamics upon LPS challenge.
Depicted are the mass intensity ranges (as indicated per heatmap) according to baseline HDL cholesterol level (A, left panels) and after
clustering analysis (B, right panels) from baseline to 24 hours after LPS infusion. In each plot, the color scale has been centered at the mid-point
between the 2% and 98% quantiles. Color values below the 2% and above the 98% quantiles have been saturated. C2; cluster 2 indicated by the
rectangle.
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Unexpectedly, we did not detect distinct differences in
HDL proteome dynamics between the two study groups
(Figure 2, left panels).
Clustering analysis
Since we did not observe a relation between baseline
HDL cholesterol levels and HDL protein dynamics after
endotoxin challenge, we investigated whether it was pos-
sible to identify individuals (in both groups) that could
be clustered using the available proteomics data. By
hierarchical clustering, the mean dynamics of all 21 rele-
vant markers intervals was computed using an agglom-
erative approach with complete linkage and one minus
the correlation as a distance measure. The right panels
of Figure 2 show the clustering of the individuals upon
LPS challenge of each of the given molecular mass
intervals. The dendrogram in Figure 4 shows that three
distinct clusters of individuals could be distinguished.
Each cluster comprised individuals with both low and
high HDL.
Serum amyloid A-1/2 and paraoxonase as markers of HDL
under inflammatory conditions
Since both serum amyloid A-1/2 (SAA-1/2) and paraox-
onase-1 (PON1) may determine the function of HDL,
we tested the hypothesis whether the LPS-challenged
individuals displayed a cluster or group dependent dis-
tribution for both parameters. SAA-1/2 levels as deter-
mined by ELISA show that the LPS administration
resulted in a similar increase in SAA-1/2 levels in both
groups up till t = 8 (Figure 1B). At t = 24, however, the
increase of SAA-1/2 in the low HDL group was slightly
stronger than that in the high HDL group (p < 0.05).
Given that the molecular masses of SAA-1a and SAA-
2a are 11680 and 11630 Da, respectively, the SAA
dynamics could also be followed in the SELDI-TOF MS
spectra: a clear increase of the signal was observed in the
interval between 110027 and 12003 m/z interval repre-
senting different SAA-1/2 isoforms (Figure 5). Additional
confirmation was achieved by 2-DE, showing a clear
upregulation of four SAA-1/2 isoforms after the LPS
Figure 3 Plots representing the dynamics of the intensities of the intervals of interest averaged over all individuals. The dashed lines
indicate plus/minus one standard deviation. In the x-axis the time course is indicated whereas the y-axis represents the total mean peak area.
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challenge (median 6-fold increase, p < 0.05) (Figure 6).
These isoforms were further characterized by MS ana-
lyses. By using a combination of trypsin and CNBr clea-
vage patterns, 80-90% sequence coverage was obtained.
This made it possible to identify native SAA-1a (SAA-
1.1) and native SAA-2a (SAA-2.1) as well as three
N-terminally truncated variants of each form: SAA-1a-
desArg, -desArgSer, -desArgSerPhePhe and SAA-2a-
desArg, -desArgSer, -desArgSerPhePhe (Table 2 and
figure 7a). These isoforms were also detectable in the
SELDI profiles of the study subjects as can be appreciated
in three representative examples (one per cluster) (Figure
7b). Detailed SELDI-TOF MS analyses showed that
the responses to LPS for these altogether 8 SAA-1/2
forms, with slightly different molecular masses, were not
different between the high and the low HDL-C groups
(Figure 8). However, the individuals in cluster 2 demon-
strated a much lower increase of SAA-1/2 forms in
response to LPS than the other two clusters (Figure 8).
The onset of the response was also later (> 8 h after LPS
exposure) in particular for the truncated variants. Inter-
estingly, the most truncated variants (SAA-1a- and
SAA2a-desArgSerPhePhe) had late responses in all
individuals but the levels were lower in cluster 2 already
before LPS exposure. In Figure 9, in which the mean
quantitative SAA-1/2a data over the entire time course
are given, no cluster dependent differences could be
observed.
As for SAA-1/2, PON1 levels were also similar in the
low and high HDL groups (Figure 9). Surprisingly,
PON1 levels showed a distinct cluster dependent distri-
bution. Individuals in cluster 2 were associated with the
higher PON1 levels compared to the clusters 1 and 3
(p < 0.01 and < 0.001 respectively).
Discussion
We previously showed that infusion of endotoxin at 1 ng/
kg bodyweight had different effects in healthy volunteers
with low and high HDL cholesterol levels [12]. Specifically,
we reported that the inflammatory response (tumor necro-
sis factor-alpha, IL-1beta, IL-6, IL-8, and monocyte che-
moattractant protein-1) as well as thrombin generation
(prothrombin fragment F1+2) were significantly increased in
the low HDL group. In the current study, we hypothesized
whether this discrepancy could be explained by differences
in the HDL proteome between the two study groups since
1
2
3
(1-r)
1
2
3
Figure 4 Dendrogram representing the overall clustering over the 24 hour time period. After correction for multiple measurements, 21 of
the 104 markers of interest (p < 0.05) were included in the analysis. Three distinct clusters can be appreciated containing subjects from both
the high and low HDL groups. The axis indicates one minus the correlation coefficient (1-r).
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many proteins and enzymes that are associated with HDL
play a role in inflammation and thrombosis [10,11]. Using
HDL immunocapture SELDI-TOF MS, the current analysis
shows that the HDL proteome at baseline as well as the
dynamic changes in the HDL proteome following LPS
administration were, however, not different in the low and
high HDL group.
HDL proteome is not different in individuals with low or
high HDL cholesterol as assessed by SELDI-TOF MS
Using a standardized LPS challenge protocol that does
not affect HDL cholesterol and apo A-I protein levels
[12], 10 individuals with HDL cholesterol levels below
the 5th percentile were compared with 10 individuals
with HDL cholesterol levels above the 95th percentile.
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Figure 5 Heat-map overviews of the (mean) dynamics in the (m/z) region corresponding with SAA. Depicted are the mass intensity ranges
(as indicated per heatmap) according to baseline HDL cholesterol level (left upper panel) and after clustering analysis (right upper panel) from
baseline to 24 hours after LPS infusion. In each plot, the color scale has been centered at the mid-point between the 2% and 98% quantiles. Color
values below the 2% and above the 98% quantiles have been saturated. The arrows indicate the larger molecular weight SAA-1 isoform specific for
cluster 2 (C2). The lower graphs show the total SAA signal in time of SAA-1 and SAA-2 between the low and high HDL groups (middle left and
lower left graphs) and the clusters 1/3 combined and cluster 2 (middle right and lower right graph respectively (p < 0.001)).
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Following endotoxin administration, 104 marker-inter-
vals showed a raw p-value lower than 0.05 and 21
remained significant after correction for multiple com-
parisons. Most of these markers were found in the lower
m/z range of the HDL protein mass spectrum. Since we
previously identified significant differences between the
systemic inflammatory responses in the high and low
HDL groups, we expected to find differences in HDL
associated proteins at baseline and/or an effect on HDL
proteome dynamics, as readout of the differences in the
cytokine storm that was elicited by the intravenous LPS
administration. Unexpectedly, heatmaps showed that the
HDL protein dynamics were not different amongst the
high and low HDL groups at baseline and over the time
course. These data thus suggest that the differences in
HDL proteome in subjects with low and high HDL do
not explain the differences in inflammatory and pro-
thrombotic dynamics among these groups.
Identification of subgroups with different HDL proteome
dynamics
Using a bioinformatics approach (on the entire dataset),
we identified 3 distinct clusters in HDL proteome
dynamics. In line with our initial analysis, this clustering
proved largely independent of baseline HDL cholesterol
levels in 2 out of the 3 clusters which comprised 80% of
all study participants. This analysis confirms that HDL
cholesterol levels per se cannot explain why HDL is
associated with a difference in response to a LPS chal-
lenge. This result is in line with the concept that HDL
function parameters should be considered rather then
HDL cholesterol concentration when it comes to the
protective properties that are attributed to HDL [15]. In
this regard, both bioactive lipids as well as proteins are
thought to mediate specific functions of HDL which is
further supported by findings that HDL subclasses are
described to have different properties [11,16,17].
SAA-1/2 and PON1
With the definition of 3 subgroups, we studied 2 para-
meters in more detail, SAA-1/2 and PON1.
Serum amyloid-1/2 (SAA-1/2), an acute phase protein,
is known to be primarily associated with HDL [18,19].
In addition, our SELDI TOF MS data showed a clearly
increased signal in the SAA-1/2 marker interval indicat-
ing that this SAA-1/2 was indeed associated with HDL.
Figure 6 Comparison of the HDL protein pattern from one subject before (t = 0) and after (t = 8) LPS exposure. HDL was isolated from
plasma by density-gradient ultracentrifugation. Proteins (300 μg) were separated with 2-DE and detected by Sypro Ruby staining. The proteins
were quantified as fluorescence intensity per total protein fluorescence. The four SAA isoforms, as identified by mass spectrometry (see Figure 7)
shown in the t = 8 h image represent: (A) SAA-1a-desArg, -desArgSer and -desArgSerPhePhe; (B) SAA-1a; (C) SAA-2a-desArg, -desArgSer and
-desArgSerPhePhe; (D) SAA-2a.
Table 2 SAA-1 and SAA-2 variants identified in HDL with 2-DE/MS
SAA-1a Theoretical Mr /pI SAA-2a Theoretical Mr /pI
native 11 680/5.9 native 11 630/8.3
desArg 11 530/5.5 desArg 11 470/6.8
desArgSer 11 440/5.5 desArgSer 11 380/7.0
desArgSerPhePhe 11 140/5.5 desArgSerPhePhe 11 090/6.8
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analyzed by peptide mass fingerprinting after CNBr cleavage. (1) Full-length N-terminal peptide-mass detected in two of the isoforms identified
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Figure 8 Dynamics of the SAA-1a and SAA-2a variants. A. The SAA dynamics between the low and high HDL group of SAA-1a (left
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The masses which correspond with the SAA variants
appear also in the top 10 ranking of the found relevant
markers which changed upon LPS challenge thereby
confirming that SAA is one of the proteins having a
major contribution to the cluster classification. SAA
association with HDL was confirmed by 2-D gel electro-
phoresis of the HDL proteome after isolation of HDL by
ultracentrifugation. The 2-DE/MS approach also verified
the presence of both SAA-1a and SAA-2a in the HDL
samples both as native and N-terminally truncated var-
iants. SAA-1a and SAA-2a have over 90% sequence
identity. Based on charge and/or molecular mass differ-
ences, the combination of 2-DE/MS and SELDI-TOF
MS made it possible to identify and measure 8 forms of
SAA-1/2. This is in accordance with previous findings
which report the presence of SAA-1/2 isoforms caused
by post-translational modifications [20,21]. Interestingly,
our results showed that all individuals in cluster 2 had a
much lower response for the SAA-1/2 isoforms after
LPS exposure. The truncated variants of cluster 2 had a
delayed response in comparison to the native forms. In
addition, the subjects in cluster 2 had lower levels of the
most truncated variant (des-ArgSerPhePhe) already
before LPS exposure. Although truncated forms of SAA-
1/2 have been described before, it is still unclear how
these modifications may affect the function. However,
our findings are in line with results showing delayed
serum response of truncated SAA-1/2 isoforms in an
individual with acute inflammation [22]. It would have
been interesting to investigate the SAA dynamics for
more than 24 hours. Unfortunately, there were no sam-
ples available of timepoints after 24 h.
PON1 is an enzyme with strong anti-oxidative proper-
ties that is primarily associated with HDL, [23,24] but
its role in cardiovascular disease is not undisputed
[17,25,26]. Although we could observe changes in inten-
sity in m/z corresponding with the PON-1 mass region,
direct identification of PON1 in the individual SELDI
spectra was not feasible in the current study. Direct
measurement of PON activity however, revealed cluster
associated differences in 2 of the 3 clusters. The indivi-
duals in cluster 2, presented the highest PON1 activity.
In the 2 other clusters, PON1 activities were similar.
Surprisingly all clusters contained individuals having
both high and low HDL cholesterol levels. It can not be
excluded that the found cluster dependent PON1 activ-
ity association may be due to genotype dependent differ-
ences in PON1 activity response [26].
Our data suggest that the differences in SAA-1/2 iso-
forms and PON1 in HDL are associated with a differen-
tial response to LPS challenge independent of HDL
cholesterol levels. However, the significance of these
findings and the underlying biological mechanisms
remain to be investigated.
Considerations
Generation of reliable HDL protein profiling data
requires careful and routine plasma collection and strict
on-chip capture conditions. The protocol used in this
study has already been reported to result in low on-chip
variability in saturation of HDL capture [9]. Based on the
virtually unchanged apo A-I and HDL cholesterol levels
(changes were less then 10%, p-value not statistical differ-
ent for both parameters) over time it was valid to assume
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Figure 9 Comparison of the clusters versus the high and low HDL cholesterol group. In the panels the overall mean (over time) serum
amyloid-A (SAA), paraoxonase (PON) levels are demonstrated of the three calculated clusters (gray bars) and the two HDLc groups (white bars).
PON levels showed only a statistical significant difference between the clusters whereas in the SAA levels no statistical significant differences
were observed at all. The error bars indicate mean ± SEM. * Indicates a statistical significant difference p < 0.01, ** indicates p < 0.001 and NS
indicates a non-significant difference.
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that the total particle number did not change to a great
extent in this study (Additional file 1, Figure S1).
In this study, we have captured HDL directly from
plasma with antibodies against apo A-I without any pre-
treatment other than freezing plasma at -80 degrees Cel-
sius prior to use. This procedure is therefore anticipated
to not largely perturb the HDL proteome. A potential
limitation in this study is that no antibodies against apo
A-II were used for capturing this specific population of
HDL particles not containing apo A-I. Through per-
forming infusions with vehicle in 4 individuals, it is
furthermore safe to state that diurnal effects did not
contribute to the observed HDL protein dynamics but
were solely the result of the endotoxin challenge.
Despite the low number of study participants we here
show that the semi-quantitative SELDI-TOF MS data,
can be used as a contributing tool to study complex bio-
logical mechanisms such as the response of humans to
an acute inflammatory challenge. However, other tools
are needed to identify the proteins in marker regions
and how they affect physiology.
Conclusions
In our initial, study we have shown that subjects with
low HDL cholesterol were more susceptible to an
inflammatory challenge compared to subjects with high
HDL cholesterol levels [12]. The current SELDI-TOF
MS study shows that differences in the HDL proteome
between these groups cannot explain this finding. This
may indicate that the susceptibility for an acute inflam-
matory challenge may be intrinsic to the HDL particle,
and not to the associated proteins on HDL. Analyzing
the data of all study participants, we identified three dis-
tinct clusters of individuals with distinctly different HDL
proteome dynamics of which SAA (isoforms) had a
major contribution. Further analyses revealed that
PON1 activity levels were associated with HDL pro-
teome changes following LPS challenge.
Additional material
Additional file 1: Figure S1. HDL cholesterol and apo A-I dynamics.
Serial change of the HDL cholesterol (upper panel) and Apo A-I lower
(panel) levels after LPS infusion (1 ng/kg body weight) of the low and
high HDL cholesterol group. Virtually no change in levels was observed
over the 24 hrs time span (P = 0.99 and 0.94 for HDL cholesterol low
and high respectively, P = 0.81 and 0.14 for apo A-I low and high
respectively)
Additional file 2: Table S1. Overview of all relevant m/z marker-
intervals upon LPS challenge. The m/z marker intervals with the
associated p-values and adjusted p-values for multiple measurements of
the LPS treated groups (LPS, n = 20) and the p-values of the healthy
subjects (Controls, n = 4) respectively. The marker intervals of the LPS
treated group are ordered according to increasing p-value. The
corresponding marker intervals in the controls show no p-value lower
than 0.05 among all the m/z intervals.
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